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Abstract 1 
 2 
Context: It remains unclear whether patients with suspicion of prostate cancer (PCa) 3 
and negative multiparametric magnetic resonance imaging (mpMRI) can safely 4 
obviate prostate biopsy. 5 
Objective: To systematically review the literature assessing the negative predictive 6 
value (NPV) of mpMRI in patients with suspicion of PCa. 7 
Evidence acquisition: The Embase, Medline and Cochrane databases were 8 
searched up to February 2016. Studies reporting pre-biopsy mpMRI results using 9 
transrectal or transperineal biopsy as reference standard were included. We further 10 
selected for meta-analysis studies with at least 10-core biopsies as reference 11 
standard, mpMRI comprising at least T2-weighted and diffusion-weighted imaging, 12 
positive mpMRI defined as a PI-5$'6/LNHUWVFRUHRIRUUHVXOWVUHSRUWHGDW13 
patient level for detection of overall PCa or clinically significant PCa (csPCa) defined 14 
DV*OHDVRQFDQFHU 15 
Evidence synthesis: 48 studies (9613 patients) were eligible for inclusion. At patient 16 
level, median prevalence was 50.4% (IQR, 36.4-57.7%) for overall cancer and 32.9% 17 
(IQR, 28.1-37.2%) for csPCa. Median mpMRI NPV was 82.4% (IQR, 69.0-92.4%) for 18 
overall cancer and 88.1% (IQR, 85.7-92.3) for csPCa. NPV significantly decreased 19 
when cancer prevalence increased, for overall cancer (r=-0.64, p<0.0001) and csPCa 20 
(r=-0.75, p=0.032). Eight studies fulfilled the inclusion criteria for meta-analysis. 21 
Seven reported results for overall PCa. When the overall PCa prevalence increased 22 
from 30% to 60%, the combined NPV estimates decreased from 88% (95% 23 
confidence interval (95% CI), 77±99%) to 67% (95% CI, 56±79%) for a cut-off score 24 
of 3/5. Only one study selected for meta-DQDO\VLV UHSRUWHG UHVXOWV IRU *OHDVRQ 25 
cancers, with a positive biopsy rate of 29.3%. The corresponding NPV for a cut-off 26 
score of 3/5 was 87.9%. 27 
Conclusion: mpMRI NPV varied greatly depending on study design, cancer 28 
prevalence, and definitions of positive mpMRI and csPCa. Because cancer 29 
prevalence was highly variable among series, risk stratification of patients should be 30 
the initial step before considering prebiopsy mpMRI and defining those in whom  31 
biopsy may be omited when the mpMRI is negative. 32 
Patient summary: This systematic review examined if multiparametric MRI scan can 33 
be used to reliably predict the absence of prostate cancer in patients suspected of 34 
 3 
having prostate cancer, thereby avoiding a prostate biopsy. The results suggest that 1 
whilst it is a promising tool, it is not accurate enough to replace prostate biopsy in 2 
such patients, mainly because its accuracy is variable and influenced by the prostate 3 
cancer risk. However, its performance can be enhanced if there were more accurate 4 
ways of determining the risk of having prostate cancer. When such tools are 5 
available, it should then be possible to use MRI scan to avoid biopsy in patients at 6 
low risk of prostate cancer.   7 
 8 
 4 
1. Introduction 1 
 2 
Correlation with radical prostatectomy specimens has demonstrated that 3 
multiparametric magnetic resonance imaging (mpMRI) has excellent sensitivity in 4 
detecting prostate cancers (PCa) ZLWKD*OHDVRQVFRUH [1-3]. As a result, prostate 5 
mpMRI is increasingly used in patients with suspicion of PCa to localize abnormal 6 
areas before biopsy. A large body of literature has shown that targeted biopsies of 7 
suspicious lesions seen on mpMRI (TBx) improved the detection of clinically 8 
significant PCa (csPCa), at least in the repeat biopsy setting [4-6]. As a result, it is 9 
now recommended that an mpMRI is performed before repeat biopsy to allow TBx of 10 
suspicious lesions in addition to standard biopsies [7]. 11 
Some authors have recently suggested that, besides improving csPCa 12 
detection, mpMRI could also be used as a triage test so that patients with negative 13 
mpMRI findings could obviate biopsy. Such a strategy remains highly controversial 14 
[8] and depends upon the negative predictive value (NPV) of mpMRI. Therefore, the 15 
European Association of Urology Prostate Cancer Guidelines Panel undertook this 16 
systematic review and meta-analysis to assess the NPV of mpMRI in patients with 17 
suspicion of PCa, and thus, its potential role in eliminating unnecessary prostate 18 
biopsy. 19 
 20 
 21 
2. Evidence acquisition 22 
 23 
2.1. Objective 24 
Our primary aim was to systematically evaluate the performance of negative 25 
pre-biopsy prostate mpMRI in predicting a negative biopsy result for overall PCa and 26 
csPCa in biopsy-naïve men and in men with previously negative biopsies. A further 27 
objective was to explore and define factors that may contribute to relevant thresholds 28 
in order to provide guidance for future studies.  29 
 30 
2.2. Data acquisition and search strategy 31 
The review was performed according to the Preferred Reporting Items for 32 
Systematic Reviews and Meta-Analysis (PRISMA) Statement [9]. The review protocol 33 
was published in PROSPERO database (http://www.crd.york.ac.uk/PROSPERO; 34 
 5 
registration number CRD42015021929). Databases searched included the Embase 1 
and OVID Medline databases, the Cochrane database of systematic reviews and the 2 
Cochrane central register for clinical trials, covering 1st January 2000 to 13th  3 
February 2016. Systematic or standard prostate biopsies were used as reference 4 
standard with positive or negative cases of PCa being determined by 5 
histopathological examination. The detailed search strategy is presented in 6 
Supplement 1.  7 
 8 
2.3. Inclusion and exclusion criteria 9 
Included studies focused on men who were assessed for suspected PCa by 10 
mpMRI before undergoing prostate biopsy. Studies enrolling both biopsy-naïve men 11 
and men who had undergone previous negative biopsies were included. Pre-biopsy 12 
prostate mpMRI was considered the index test and comprised T2-weighted imaging 13 
(T2WI) and at least one functional imaging technique (diffusion-weighted imaging 14 
(DWI), dynamic contrast-enhanced imaging (DCEI) or magnetic resonance 15 
spectroscopic imaging (MRSI)). For inclusion, studies had to report on false 16 
negatives and true negatives, in order to calculate NPV (i.e. results of 17 
systematic/standard prostate biopsies when the mpMRI was negative). When 18 
available, false positive and true positive findings were also noted to calculate the 19 
positive predictive value (PPV) and the cancer prevalence. There was neither 20 
restriction on the biopsy technique (transrectal or transperineal) nor on the number of 21 
biopsy cores. Studies using radical prostatectomy specimens as reference standard 22 
were excluded, as were studies evaluating men with histologically proven prostate 23 
cancer. Studies with less than 50 participants were excluded. No language 24 
restrictions were applied.  25 
 26 
2.4. Data collection and data extraction 27 
Two reviewers (PM, TVDB) independently screened all abstracts and full-text 28 
articles for eligibility. Disagreement was resolved by discussion or reference to an 29 
independent third party (LM). All screening was performed using a pre-defined 30 
eligibility form.  31 
Using a data extraction form developed a priori, the same two reviewers 32 
independently extracted data concerning study methodology, patient characteristics, 33 
technical characteristics of the MR scanners, mpMRI protocol, mpMRI scoring 34 
 6 
system, definition of positive mpMRI, biopsy protocol and definition of csPCa. Any 1 
discrepancies concerning data extraction were resolved by consensus, or reference 2 
to an independent arbiter (OR or TBL).  3 
 4 
2.5. Risk of publication bias  5 
To assess the risk of bias, all included reports were reviewed using the Quality 6 
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for diagnostic 7 
accuracy studies [10].  8 
 9 
2.6. Data synthesis and analysis 10 
Outcome data regarding false negative and true negative values of mpMRI 11 
before prostate biopsy were recorded as reported by authors. When not available, 12 
data were indirectly derived from specificity, sensitivity and prevalence values 13 
reported by authors using an online Bayesian statistics calculator 14 
(http://www.medcalc.com/bayes.html). Descriptive statistics were used to summarise 15 
baseline characteristics and outcomes, including median and interquartile range 16 
(IQR) for estimates of NPV across studies. Correlation between mpMRI NPV and 17 
positive biopsy rate was done usLQJWKH3HDUVRQ¶VFRUUHODWLRQFRHIILFLHQW. 18 
A meta-analysis was undertaken to calculate pooled NPV and PPV. To ensure 19 
appropriate clinical homogeneity of the studies included in the meta-analysis, we 20 
selected only the studies enrolling biopsy-naïve patients and/or patients with history 21 
of negative biopsy, and fulfilling the following criteria that were defined a priori: (i) 22 
reference standard consisting of prostate biopsy with at least 10 samples on all 23 
patients; (ii) mpMRI protocol comprising at least T2WI and DWI; (iii) mpMRI results 24 
presented as a 5-level score, using a subjective Likert scale or the Prostate Imaging 25 
Reporting Data System (PI-RADS) score [11]; (iv) definition of positive mpMRI as a 26 
VFRUHRU; and (v) results reported on a per patient basis. In addition, only 27 
VWXGLHVGHILQLQJFV3&DDV*OHDVRQFDQFHUVZHUHVHOHFWHGIRU WKHPHWD-analysis 28 
assessing the mpMRI NPV for csPCa. A bivariate random effects approach was 29 
employed using the Midas package in Stata 12 (StataCorp LP, Texas, USA). Since 30 
the NPV decreases and the PPV increases as the prevalence increases, post-test 31 
probability estimates of NPV and PPV were reported for given values of the 32 
prevalence EDVHGRQ%D\HV¶WKHRUHP.  33 
 7 
For other studies not included in the meta-analysis based on the criteria 1 
described above, a narrative synthesis of the data was performed. To explore and 2 
define clinical heterogeneity, subgroups were analysed at patient level based on the 3 
following variables: biopsy-naïve versus previous negative biopsy; patients with 4 
positive versus negative DRE; mpMRI perfomed with an endorectal versus without 5 
an endorectal coil; transrectal ultrasound (TRUS) versus template transperineal 6 
(TTP) biopsy approach; and 16 cores versus >16 cores as reference standard. 7 
6WXGLHV UHSRUWLQJ PS05, 139 IRU SDWLHQWV ZLWK D 36$ OHYHO  QJP/ ZHUH DOVR 8 
reported separately . 9 
 10 
3. Evidence synthesis 11 
 12 
3.1. Quantity of evidence identified 13 
The study selection process is depicted in the PRISMA flow diagram (Fig. 1). A 14 
total of 2,980 abstracts were retrieved. After abstract screening and removal of 15 
duplicates, 240 articles were eligible for full text screening, of which 48 studies were 16 
eligible for inclusion [12-59]. 17 
 18 
3.2. Quality of studies 19 
Out of the 48 included studies, 42 were single-centre and 6 were multi-centre 20 
studies. Thirty-four studies were prospective, 6 were retrospective whilst the design 21 
of the rest was unclear. Risk of bias (RoB) assessment using QUADAS-2 was 22 
performed for each of the individual studies (Fig. 2a-2b). Overall, the RoB was highly 23 
heterogeneous across studies for all criteria, except for the reference standard 24 
domain, in which RoB was low in most studies. 25 
 26 
3.3. Characteristics of studies 27 
The 48 studies comprised a total of 9,613 men who underwent prostate mpMRI 28 
followed by biopsy. The study and patient baseline characteristics are presented in 29 
Table 1. The patient population consisted of biopsy-naive men in 9 studies, men with 30 
at least one previous negative biopsy in 16 studies, and both biopsy-naïve men and 31 
men with history of previous negative biopsy in 9 studies. In 14 studies, the biopsy 32 
history of the patients was unclear.  33 
 8 
The magnetic field strength was 1T, 1.5T and 3T in 1, 28 and 15 studies, 1 
respectively. Four studies used both 1.5T and 3T MR systems. DWI and DCEI were 2 
used in 36 and 35 studies, respectively. Nineteen studies also added MRSI. An 3 
endorectal coil was used in 18 studies. The definition of positive mpMRI varied 4 
across studies. The PI-RADS v1 score was used in 12 studies, a 5-level subjective 5 
(Likert) score was used in 8 studies and one study reported data based on the 2 6 
scoring systems. In-house criteria were used in 13 studies for defining positive 7 
mpMRI, and 5 studies used a dichotomous definition. Nine studies did not report on 8 
the criteria for positive mpMRI. No study used the PI-RADS v2 score. 9 
Regarding the reference standard, TRUS-guided biopsies were used in 39 10 
studies, TTP biopsies in 6 studies and mixed TRUS-guided and TTP biopsies in 2 11 
studies. In one study, the biopsy approach was unclear. The number of cores per 12 
biopsy procedure was 16 in 30 studies, >16 in 9 studies and variable among 13 
patients in 3 studies. For 6 studies, the number of biopsy cores taken was unclear.  14 
 15 
3.4. Negative predictive value of pre-biopsy mpMRI 16 
At patient level, median biopsy positivity rate (i.e. cancer prevalence) was 17 
50.4% (IQR, 36.4-57.7%) for overall cancer and 32.9% (IQR, 28.1-37.2%) for csPCa 18 
(Table 2). Median mpMRI NPV was 82.4% (IQR, 69.0-92.4%) for overall cancer and 19 
88.1% (IQR, 85.7-92.3) for csPCa. NPV significantly decreased when cancer 20 
prevalence increased, both for overall cancer (r=-0.64, p<0.0001) and csPCa (r=-21 
0.75, p=0.032; Fig 3). In addition, NPV was highly dependent on the definition used 22 
for csPCa, with differences of up to 21% when several definitions were used in the 23 
same dataset [12, 13, 38, 47, 48].  24 
Cancer prevalence tended to be higher and mpMRI NPV lower in the biopsy-25 
naïve group as compared to the repeat biopsy group, in men with positive DRE as 26 
compared to men with negative DRE and when an endorectal coil was not used 27 
(Table 3). There were no clear differences in prevalence and NPV in the other 28 
analysed subgroups (TRUS-guided versus TTP biopsy, biopsy procedures with 16 29 
cores versus >16 cores; Table 3). However, comparisons must be interpreted with 30 
care, due to the small number of studies in some subgroups. In patients with a PSA 31 
OHYHO  QJP/ PHGLDQ 139 IRU RYerall PCa was 86.3% (IQR, 73.3-93.6%) for a 32 
median cancer prevalence of 35.4% (IQR, 27.6-42.5%). 33 
 34 
 9 
3.5. Meta-analysis  1 
 2 
3.5.1. NPV and PPV for overall PCa 3 
Eight studies reported NPV at patient level for overall PCa and fulfilled the 4 
inclusion criteria for meta-analysis (Table 4) [22, 25, 38, 41, 43, 46, 56, 57].  5 
Seven studies uVHGDVFRUHRIIRUGHILQLQJDSRVLWLYHPS05,)LJXUHs 4a-b) 6 
[22, 25, 38, 43, 46, 56, 57]. Figure 4c shows the conditional probability plot of 1-NPV 7 
and PPV as a function of overall PCa prevalence. Table 5 shows NPV and PPV 8 
estimates for given values of PCa prevalence. 9 
Only 3 studies XVHGDVFRUHRIIRUGHILQLQJDSRVLWLYHPS05,Table 4) [41, 10 
46, 57], and a formal meta-analysis could not be performed. 11 
 12 
3.5.3. NPV and PPV for Gleason  cancers  13 
Only one study reporting NPV at patient level for *OHDVRQFDQFHUs met the 14 
selection criteria for inclusion in the meta-analysis. It reported NPV and PPV of 15 
87.9% and 45.1% respectively, for a prevalence of 29.3% (Table 4) [46].  16 
 17 
3.6. Discussion 18 
 19 
3.6.1. Principal findings 20 
We observed a large variability in reported NPV. Many factors can explain this 21 
variability, such as differences in mpMRI protocols, definition of negative mpMRI, or 22 
biopsy protocols. However, two major causes of variability must be pointed out. First, 23 
the cancer prevalence was highly variable, ranging at patient level from 13% to 24 
74.7% for overall PCa, and from 13.7% and 50.9% for csPCa. This variability was 25 
observed both in the biopsy-naïve and repeat biopsy setting. Because NPV depends 26 
on prevalence, this had a major impact on reported NPV (Fig 3). Second, the 27 
definition of csPCa was highly variable from one series to another, and differences of 28 
up to 21% could be observed in NPV when different definitions of csPCa were used 29 
in the same dataset [12, 13, 38, 47, 48]. 30 
To account for clinical heterogeneity, and to further explore the clinical 31 
relevance of the results, we carefully selected studies for inclusion in the meta-32 
analysis based on stringent criteria. Particularly, we included only studies that: (i) had 33 
biopsy protocols with at least 10 cores, since it is no longer recommended to obtain 34 
 10 
less than 10 cores per biopsy; (ii) used diffusion-weighted imaging, which is the most 1 
informative technique, at least for cancers in the peripheral zone [60]; and (iii) 2 
reported mpMRI findings using a 5-level score, so that negative findings could be 3 
better defined. We accepted studies using a subjective (Likert) scale because 4 
experienced readers obtained equivalent [45, 61, 62] or better [63] results with the 5 
Likert score than with the PI-RADS v1 score. Because of the large variations of NPV 6 
induced by differences in definitions of csPCa, we did not include different definitions 7 
in the meta-analysis since this would have introduced unacceptable clinical 8 
heterogeneity in the results, possibly resulting in erroneous and biased estimates. 9 
We therefore a priori restricted the definition of csPCa to cancers with a Gleason 10 
VFRUH  JLYHQ WKH low lethal potential of Gleason 6 cancers [64] and the lack of 11 
consensus among pathologists on the best method to measure biopsy core invasion 12 
length [65, 66]. 13 
In this more homogeneous group of studies, the prevalence range was still 14 
large (31.3%-63.7%). As a result, we modelled the evolution of NPV (and PPV) as a 15 
function of overall PCa prevalence. Unfortunately, we could not duplicate this for 16 
csPCa since only one study reporting NPV for *OHDVRQ cancers met the inclusion 17 
criteria for meta-analysis. 18 
 19 
3.6.2. Reference standard 20 
We included only studies that reported the results of systematic/standard biopsy 21 
in patients with a negative mpMRI, and used the systematic/standard biopsy as a 22 
reference standard. It is well known that TRUS-guided biopsy harbours both random 23 
and systematic errors, as evidenced by the high rates of positivity of immediate 24 
repeat biopsy after a first series of negative biopsies [67, 68], and as confirmed 25 
recently by the PROMIS trial  [69]. Therefore, using TRUS-guided biopsy as a 26 
reference standard may have overestimated the NPV of mpMRI. However, studies 27 
using radical prostatectomy specimens as a reference standard have already 28 
reported the mpMRI detection rates in relation to PCa Gleason score and volume [1]. 29 
In this review, we intended to address the more pragmatic question as to whether a 30 
negative mpMRI could predict a negative subsequent biopsy. This is an important 31 
question because if the NPV of mpMRI was sufficiently high in comparison with the 32 
reference standard of systematic/standard biopsies, then in practice a negative 33 
mpMRI result could indeed avoid the need for prostate biopsy. Therefore, studies 34 
 11 
reporting only biopsy results when the mpMRI was positive (e.g. obtained through 1 
MRI-targeted, guided or fusion biopsies with added systematic biopsies) were not 2 
included in this review. 3 
 4 
3.6.3. Impact on clinical practice and research 5 
It is now well established that mpMRI is a sensitive tool for detecting aggressive 6 
PCa [1-3, 69]. However several reasons preclude its broad use as a triage test 7 
before biopsy.  8 
Firstly, the population referred to prostate biopsy is not standardized. The large 9 
range of reported prevalence for overall PCa and csPCa suggests substantial 10 
heterogeneity in the way patients are selected for biopsy. Because of this 11 
heterogeneity, we did not provide a pooled estimate for mpMRI NPV. The role of 12 
mpMRI as a triage test before prostate biopsy should be evaluated in the broader 13 
context of the selection of patients with suspicion of (aggressive) PCa. In a recent 14 
UHWURVSHFWLYHVWXG\RISDWLHQWVPS05,139 IRU*OHDVRQFDQFHUs was 91% 15 
ZKHQWKH36$GHQVLW\ZDVQJP/P/DQGRQO\ZKHQWKH36$GHQVLW\ZDV16 
>0.2 ng/mL/mL (p=0.003) [70]. In another series of 288 biopsy-naïve patients, no 17 
FV3&D*OHDVRQVFRUHRUPD[LPXPFDQFHUFRUHOHQJWKPP) was found in the 18 
44 patients with a PSA density <0.15 ng/mL/mL and a PI-RADS v2 score <3/5 [71]. 19 
We believe that such a pre-stratification of the risk of csPCa is an interesting way for 20 
rationalizing the use of mpMRI before biopsy. Patients found at very low risk would 21 
be spared both mpMRI and biopsy. Patients at low risk - for whom mpMRI would 22 
have a NPV high enough to be used as a triage test - could avoid biopsy in case of 23 
negative mpMRI. Patients at higher risk would need biopsy even in case of negative 24 
mpMRI. Many tools can be used to risk-stratify the population of patients referred to 25 
biopsy, ranging from simple parameters such as PSA density to more complicated 26 
risk calculators [72, 73]. The impact of these tools on the NPV of pre-biopsy mpMRI 27 
needs to be carefully evaluated, both in the biopsy naïve and in the repeat biopsy 28 
setting. For the moment, it is impossible to make any recommendations on the best 29 
way to risk-stratify patients before referring them for mpMRI. 30 
Secondly, the large variability in the definition of csPCa precludes any definitive 31 
conclusion on the ability of mpMRI to rule out aggressive cancer. The issue of the 32 
most appropriate definition of csPCa on biopsy is complex, since biopsy results may 33 
neither accurately reflect tumour burden nor aggressiveness. Nonetheless, there is 34 
 12 
an urgent need to standardize the histological definition(s) of csPCa, to allow 1 
meaningful comparisons between studies.  2 
Thirdly, the specificity of mpMRI remains moderate, and there is a substantial 3 
proportion of false positives in the lesions scored 3/5 or 4/5 [1, 74, 75], even with the 4 
new PI-RADS v2 score [76]. In a series of 62 patients with 116 lesions biopsied 5 
under magnetic resonance/ultrasound fusion, the overall cancer detection rates for 6 
PI-RADS v2 scores of 3/5 and 4/5 were only 15.8% and 29.8%. [77]. In theory, a 7 
triage test used to rule out a disease needs to be highly sensitive for this disease. 8 
However, if its specificity is too low, it will be clinically useless since most patients will 9 
be positive, whether they have the disease or not. Therefore, if mpMRi is to be used 10 
as a triage test in the future, there is a need to improve its specificity. This could be 11 
achieved by a continuous refinement of scores [78]. Promising results in 12 
characterizing csPCa have also been reported with quantitative analysis [79]. 13 
Finally, all published studies were performed in specialized centres. The broad 14 
use of mpMRI as a triage test assumes good inter-observer reproducibility. 15 
Unfortunately, inter-observer reproducibility of existing scoring systems remains 16 
moderate [62, 63, 80] even with the use of the PI-RADS v2 score [80, 81]. Studies 17 
evaluating on a large scale the reproducibility of mpMRI findings between expert and 18 
non-expert centres are currently lacking. 19 
 20 
3.6.3. How this review compares with other reviews 21 
Three systematic reviews (including two meta-analyses) regarding the role of 22 
mpMRI in localized prostate cancer have been published recently [4-6]. Crucially, all 23 
three reviews focused exclusively on the sensitivity of mpMRI-targeted, guided or 24 
fusion biopsies in diagnosing overall PCa and csPCa, using TRUS-guided prostate 25 
biopsies as reference standard. The impact of systematic biopsies on the outcome 26 
was not addressed in any of the reviews, either within the index test or the reference 27 
standard. Our review had a totally different research question and objective, focusing 28 
on NPV of mpMRI to see if a negative mpMRI can avoid the need for a prostate 29 
biopsy. Because MRI-targeted/guided/fusion biopsies are not relevant if the mpMRI 30 
was negative for cancer, it can be argued that the 3 reviews assessed a different 31 
index test altogether. As such, we believe the findings of this review are novel and 32 
unique, and pave the way for further focused clinical studies.       33 
 34 
 13 
3.6.4. Strengths and limitations 1 
The current study represents the first systematic review addressing the role of 2 
mpMRI as a triage test before biopsy. The review elements were developed in 3 
conjunction with a multidisciplinary panel of experts (EAU Prostate Cancer guidelines 4 
panel), which included a patient representative, and the review was performed 5 
robustly in accordance with recognised standards. However, it is limited by the major 6 
heterogeneity of the existing literature in patient population, study design, and 7 
definitions of positive mpMRI and csPCa. It highlighted further areas of research that 8 
could help in defining the best use of mpMRI in the early detection of aggressive 9 
prostate cancer in the future.  10 
 11 
4. Conclusion 12 
Although mpMRI can detect aggressive prostate cancer with excellent 13 
sensitivity, a definitive conclusion on its role as a triage test before prostate biopsy 14 
will be possible only when three main issues are addressed. Firstly, because NPV 15 
depends on prevalence, and because overall PCa and csPCa prevalence was highly 16 
variable in the published series, it becomes mandatory to define the optimal way to 17 
pre-evaluate the risk of csPCa in patients with suspicion of PCa. Depending on the 18 
risk category, mpMRI could then be used to obviate biopsies or not. Secondly, there 19 
is a need for consensus definitions of csPCa on biopsy findings to allow inter-study 20 
comparisons. Thirdly, although efforts have been made to standardize mpMRI 21 
technical protocols and interpretation in the past few years [11, 60, 76], there is still a 22 
crucial need to improve mpMRI specificity and inter-reader reproducibility. 23 
 24 
Legends for figures: 25 
 26 
Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-analysis 27 
(PRISMA) flow chart. 28 
 29 
Figure 2: (A) Assessment of the risk of bias for included studies; (B) risk of bias 30 
summary graph. 31 
 32 
 14 
Figure 3: Negative predictive value of Pre-biopsy multiparametric MRI as a function 1 
of cancer prevalence (blue crosses: overall prostate cancer; red crosses: clinically 2 
significant prostate cancer). 3 
The blue line is the correlation line for overall prostate cancer; the red dotted line is 4 
the correlation line for clinically significant prostate cancer. 5 
 6 
Figure 4:  7 
(A-B): Forest plot showing the negative predictive value (NPV; Fig 4A) and positive 8 
predictive value (PPV; Fig 4B) of pre-biopsy multiparametic MRI for overall prostate 9 
cancer in the seven studies selected for meta-analysis that used a cut-off score of 10 
IRUGHILQLQJSRVLWLYH05, 11 
Studies have been ranked according to cancer prevalence (left column). Intervals in 12 
the right column are 95% confidence intervals (95% CI) of the NPV (Fig 4A) or PPV 13 
(Fig 4B). Because NPV and PPV vary with cancer prevalence, combined estimates 14 
of NPV and PPV have not been provided. 15 
(C) Conditional probability plot showing the estimation of the combined NPV and 16 
PPV in the seven studies, as a function of the prevalence of overall prostate cancer. 17 
The x axis (prior probability) indicates the overall prostate cancer prevalence. The y 18 
axis (posterior probability) indicates either PPV (dashed line, upper quadrant) or 1-19 
NPV (dotted line, lower quadrant). 20 
 21 
 15 
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